Get All Access for FREE

Market News & Research,
Fundamental Data,
Live Transcripts & Audio,
AlphaGraphics,

and a whole lot more…

{{::item.ticker}} • {{::item.company_name}} No Results

Get All Access for FREE

Market News & Research,
Fundamental Data,
Live Transcripts & Audio,
AlphaGraphics,

and a whole lot more…

News & Research
Portfolio
Discover
Groups
$AGN {{ '2016-02-08T15:45:49+0000' | timeago}} • Announcement

$PFE said Bill Meury, currently EVP and President Branded Pharma at $AGN, will become Group President, Global Specialty and Consumer Brands, Pfizer. Following closing, $PFE will continue to manage the combined company's commercial operations through two distinct businesses: Innovative Products business and Established Products business.

$AGN {{ '2018-02-06T21:23:10+0000' | timeago}} • Infographic

$AGN Allergan Plc Earnings AlphaGraphic: Q4 2017 Highlights

$AGN {{ '2018-02-06T17:23:26+0000' | timeago}} • Announcement

For FY18, $AGN expects its total net revenues to be in the range of $15.0 -15.3Bil and net loss per share is expected to be about $2.27-1.52. The company expects its 1Q18 total net revenues to be about $3.5-3.6Bil and net loss per share of about $1.27-1.07.

$AGN {{ '2018-02-06T17:17:53+0000' | timeago}} • Announcement

Drugmaker $AGN reported a profit for 4Q17 on strong demand for Botox. Net earnings came to $3.05Bil, or $8.88 per share, compared with a  year-earlier loss of $70.2MM, or $0.20 loss per share. Adj. EPS was $4.86. Revenue rose 12% YoY to $4.33Bil, helped by the sales growth in drugs like Botox, Alloderm and Juvederm collection.

$AGN {{ '2018-02-01T13:45:14+0000' | timeago}} • Announcement

$AGN agreed to pay $700MM to $TEVA to settle their working capital dispute arbitration. Teva expects to receive this payment from Allergan in 1Q18 and use this amount for repaying a portion of its term loan debt. As of Jan. 12, 2018, Allergan owns 6.8% of Teva shares.

$AMGN {{ '2018-01-19T13:28:13+0000' | timeago}} • Announcement

The European Commission (EC) has granted marketing authorization for MVASI from $AMGN and $AGN. MVASI is the first biosimilar bevacizumab approved by the EC and is approved for the treatment of certain types of cancers.

$AGN {{ '2018-01-17T13:14:16+0000' | timeago}} • Announcement

$AGN and $IRWD reached an agreement with Indian pharma company Sun Pharma to resolve a patent litigation for the generic version of constipation drug Linzess in the U.S. As per the agreement, Sun Pharma will be able to market the generic version of Linzess in the U.S. from Feb. 1, 2031. All the litigations related to Linzess were dismissed.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$AGN {{ '2017-12-21T14:38:43+0000' | timeago}} • Announcement

$AGN and its partner $PRTK announced that FDA accepted to review Seysara, an investigational drug for treating acne. Allergan, which has the U.S. rights of developing and marketing Seysara, expects FDA to take action on this in 2H18. Paratek retains the non-U.S. rights. In March 2017, Allergan announced positive results from Seysara Phase 3 trials.

$AGN {{ '2017-12-18T22:26:29+0000' | timeago}} • Announcement

Robert Stewart, COO of $AGN will resign from his role. He has been named as the CEO of the newly formed Amneal Pharmaceuticals, effective Jan. 25, 2018. Following Rob's departure, Wayne Swanton, SVP, Global Operations has been promoted as EVP, Global Operations of Allergan.

$AGN {{ '2017-12-18T22:14:14+0000' | timeago}} • Announcement

$AGN and its development partner Gedeon Richter Plc reported positive results from phase 3 study of cariprazine, which is used to treat the bipolar depression. Allergan plans to file the New Drug Application to the FDA in 2H18.

$IPXL {{ '2017-12-18T13:05:53+0000' | timeago}} • Announcement

Amneal Pharmaceuticals LLC and $IPXL said Robert Stewart will join Amneal as President, effective Jan. 25, 2018. Stewart most recently served as COO of $AGN. After completion of combination of Amneal and $IPXL, Stewart will become President and CEO of the combined company, to be named Amneal Pharmaceuticals Inc., and will become a BoD member.

$AGN {{ '2017-12-12T19:58:45+0000' | timeago}} • Announcement

$AGN gets FDA clearance for the CoolSculpting, a treatment to improve the appearance of lax tissue in double chin. Allergan got this CoolSculpting technology by acquiring Zeltiq Aesthetics in Feb. 2017 for $2.4Bil. Allergan added that in an 18-week study, 77% of patients showed improved appearance in their lax tissue.

$AGN {{ '2017-12-12T19:07:05+0000' | timeago}} • Announcement

$AGN enters into a buyout deal with $RPRX through a cash tender offer of $0.67 per share, representing a 43% premium of Repros Therapeutics’ Dec. 11th closing price ($0.47). Allergan's subsidiary will acquire Repros, which focuses on developing the drugs for male and female reproductive disorders. The deal is expected to close in 1Q18.

$AGN {{ '2017-12-05T18:08:04+0000' | timeago}} • Announcement

Revance Therapeutics reported positive data for RT002, an injectable drug which would treat glabellar or frown lines. With positive results from the two Phase 3 trials, $AGN's rival plans to complete the third Phase 3 trial in 2H18 and file for FDA approval in 1H19, and introduce the competitive drug for Allergan's Botox in the U.S. in 2020.

$AGN {{ '2017-11-03T20:08:36+0000' | timeago}} • Announcement

$AGN, which was criticized by the Federal Court recently on its Restasis deal, narrowed its revenue outlook for FY17. Allergan also widened its GAAP loss from the previous estimate, reflecting the generics competition and the potential patent losses. With regards to the Federal Court's decision on Restasis drug, the company had filed an appeal.

$AGN {{ '2017-11-03T19:30:46+0000' | timeago}} • Announcement

Despite an increase in revenue, $AGN swung to a loss in 3Q17, hurt by impairment charges related to its Restasis drug and Teva stake holding. Net loss was $4.03Bil or $12.07 per share versus net income of $15.2Bil or $38.58 per share a year ago. Revenue rose 11% to $4.03Bil, helped by the sales growth in drugs like Botox and Juvederm collection.

$AGN {{ '2017-11-01T14:05:00+0000' | timeago}} • Infographic

$AGN Allergan Plc Earnings AlphaGraphic: Q3 2017 Highlights

$MYL {{ '2017-10-17T16:40:23+0000' | timeago}} • Announcement

$MYL announced that the United States District Court for the Eastern District of Texas issued a decision finding all asserted claims of the patents relating to Restasis invalid. The Court recognized that $AGN's patent protection for Restasis ended in 2014.

$AGN {{ '2017-10-16T21:26:34+0000' | timeago}} • Announcement

Drugmaker $AGN gets an adverse effect from the U.S. District Court for the Eastern District of Texas. The judge invalidated Allergan's Restasis patent deal, which was signed with the Mohawk Tribe in the last month. Allergan plans to appeal the ruling. Restasis, a dry-eye treatment drug,  generated $1.5Bil of revenues for Allergan in 2016.

Recent Transcripts
ABT | Earnings
April 18th 2018, 1:00pm
ARNA | Earnings
March 14th 2018, 12:30pm
VRML | Earnings
March 13th 2018, 8:30pm
CRY | Earnings
March 8th 2018, 1:00pm
AlphaGraphics you may like
Related Feed
Recent Transcripts
ABT | Earnings
April 18th 2018, 1:00pm
ARNA | Earnings
March 14th 2018, 12:30pm
VRML | Earnings
March 13th 2018, 8:30pm
CRY | Earnings
March 8th 2018, 1:00pm
AlphaGraphics you may like